Filter
4948
Filtered Results: 4948
Text search:
patient
safety
Featured
Recommendations
576
New Publications
1251
Language
Document type
No document type
2561
Guidelines
880
Studies & Reports
675
Manuals
310
Strategic & Response Plan
187
Fact sheets
121
Training Material
81
Situation Updates
51
Resource Platforms
23
Brochures
21
Infographics
15
Online Courses
14
Videos
8
App
1
Countries / Regions
India
221
Global
164
Sierra Leone
139
Kenya
134
Liberia
131
South Africa
124
Nigeria
105
Western and Central Europe
102
Ethiopia
97
Uganda
81
Africa
64
Ghana
63
Latin America and the Carribbean
63
Tanzania
62
Syria
61
Malawi
61
Zambia
58
Nepal
55
Rwanda
55
Myanmar / Burma
55
Bangladesh
53
Guinea
45
Philippines
44
Namibia
44
Russia
40
Ukraine
35
Congo, Democratic Republic of
33
West and Central Africa
32
Eastern Europe
31
Senegal
30
Middle East and North Africa
30
Germany
27
Indonesia
27
South–East Asia Region
27
Zimbabwe
26
South Sudan
26
Brazil
26
East and Southern Africa
26
Lesotho
25
Burkina Faso
23
Haiti
23
Cambodia
23
Eastern Europe and Central Asia
23
Mali
19
Asia
19
USA
18
Mozambique
18
Botswana
17
Yemen
17
Eswatini/ Swaziland
14
Cameroon
13
Côte d’Ivoire / Ivory Coast
11
Western Pacific Region
11
Pakistan
10
Sudan
10
Colombia
10
Venezuela
9
Guinea-Bissau
8
Afghanistan
8
Angola
8
Chile
8
Laos
8
United Kingdom
8
Iraq
7
Madagascar
7
Albania
7
Tajikistan
7
Vietnam
7
Lebanon
6
Benin
6
Central African Republic
6
Argentina
6
Peru
6
Somalia
5
Jordan
5
Thailand
5
Bolivia
5
Sri Lanka
5
Palestine
5
Turkey
4
Chad
4
Paraguay
4
Bhutan
4
Southern Africa
4
Moldova
4
Georgia
4
North America
4
Spain
4
Niger
3
Togo
3
Gambia
3
China
3
Singapore
3
Burundi
3
Ecuador
3
Libya
3
Canada
3
Mauritius
3
Saudi Arabia
2
North Macedonia
2
Switzerland
2
El Salvador
2
Greece
2
Timor Leste/ East Timor
2
Lithuania
2
France
2
Morocco
1
Egypt
1
Ireland
1
Papua New Guinea
1
Austria
1
Serbia
1
Honduras
1
Guatemala
1
Mexico
1
Nicaragua
1
Fiji
1
Poland
1
Italy
1
Armenia
1
Congo-Brazzaville
1
Qatar
1
Bulgaria
1
Estonia
1
Romania
1
Iran
1
Uzbekistan
1
Kyrgyzstan
1
Australia
1
Kazakhstan
1
Gabon
1
Turkmenistan
1
Jamaica
1
Japan
1
Denmark
1
Belgium
1
Maldives
1
Portugal
1
French Guyana
1
Israel
1
Latvia
1
Authors & Publishers
Publication Years
Category
Countries
1717
Clinical Guidelines
495
Public Health
271
Key Resources
243
Women & Child Health
223
Capacity Building
102
Pharmacy & Technologies
81
Toolboxes
COVID-19
650
Mental Health
377
HIV
291
TB
253
Ebola
252
Caregiver
229
AMR
225
Rapid Response
185
Pharmacy
171
Conflict
122
NTDs
100
Planetary Health
95
Refugee
89
NCDs
84
Disability
74
Global Health Education
60
Natural Hazards
47
Specific Hazards
42
Cholera
37
Zika
34
Polio
23
Health Financing Toolbox
14
Social Ethics
12
South Sudan
1
Typhoon
1
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
The guide is suitable and can be used for the following audiences:
1. nurses and other trained healthcare workers who can use this manual as a self-study tool and then incorporate its guidance into their practice;
2. governmental and non-governmental employers of lay and professional TB treatment ...
Thesis presented in partial fulfilment of the requirements for the degree of Master of Nursing Science in the Faculty of Health Sciences at Stellenbosch University.
The mobile clinic health care services fulfil an essential role in delivering primary health care to the dwellers in the rural commun...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The ...-centred platform aims to facilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
The new WHO recommendations for rabies immunization supersede the 2010 WHO position
on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for rabies. These updated
recommendations are based on new evidence and directed by public health needs that are cost-,
dose- and time-sparing...
Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in ... with non-severe COVID-19
The guidance includes updated risk rates for hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
This paper explores the angles and opportunities of digital health, with a look
at digital innovation and its potential to support patients with circulatory diseases.
In reviewing developments in the field, current applications as well as gaps, th...
sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapte...
The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio...
The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchia...
The main objectives of these guidelines are to:
1. contribute to the quality assurance of medicinal plant materials used as the source for herbal medicines to improve the quality, safety and efficacy of finished herbal products; 2. guide the f...
1. contribute to the quality assurance of medicinal plant materials used as the source for herbal medicines to improve the quality, safety and efficacy of finished herbal products; 2. guide the f...
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients<...
Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
PLOS ONE | www.plosone.org 1, May 2013 | Volume 8 | Issue 5 | e64915
Expert Consensus Validation 2018.
This innovative approach aimed at improving and facilitating the screening, prescribing and monitoring of drug therapy for older patients, is currently being further developed in the area of Clinical Pharmacology a...
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat pat... with COVID-19 needing mechanical ventilation. However, neither of these studies were peer-reviewed nor formally published and one of them was later retracted.
WHO Academy’s mobile learning app
recommended
The WHO Academy’s mobile learning app was developed specifically for health workers and is designed to enable them to expand their life-saving skills to battle COVID-19. It delivers mobile access to a wealth of COVID-19 knowledge resources developed by WHO, including up-to-the-minute guidance, to...
28 January 2021. The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients.
Laboratory testing for the monkeypox virus
recommended
Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is base...
